Eurofins reinforces its specialty clinical diagnostics footprint by acquiring PerkinElmer’s NTD laboratory services business
Monday, April 25, 2016
Eurofins Scientific (EUFI.PA), the global leader in bio-analytical testing, and one of the world leaders in genomic services, announces that it has acquired PerkinElmer, Inc.'s U.S. prenatal screening laboratory services business PerkinElmer Labs/NTD ("NTD").
Founded more than 30 years ago, NTD is a reference laboratory in the US for first and second trimester prenatal screening. It has pioneered the research and development of prenatal screening protocols and offered the first biochemical screening test for early onset preeclampsia. NTD's first trimester non-invasive prenatal screening test for Down Syndrome is the only high sensitivity screen that uses the free Beta hCG biomarker, along with PAPP-A and Nuchal Translucency measurement, in assessing risk for Down syndrome.
The company generated revenues of about US$ 20m in 2015 and employs approximately 80 staff at its laboratory in Melville, NY, serving universities, hospitals, maternal fetal medicine specialists, and other laboratories worldwide.
The acquisition of NTD strengthens Eurofins' growing footprint in the genetics segment of the specialty clinical diagnostic testing market. NTD's expertise in reproductive genetic testing is fully complementary to the Group's leading position in expanded carrier testing capabilities, and expands Eurofins' analytical portfolio for genetic disorders, established through the acquisition of Emory Genetics Laboratory ("EGL") in 2015, a joint venture with Emory University. The addition of NTD into Eurofins' laboratory network further strengthens the Group's pharmaceutical and clinical service offering and advances its development into a leading presence in the specialty clinical testing services for hospitals, clinicians and pharmaceutical companies.
Comment from Dr. Gilles Martin, Eurofins CEO: "This acquisition reflects our strategy of expanding and strengthening our network of competence centers. NTD strengthens Eurofins' testing capabilities for genetic disorders, and the Group's footprint in the specialty clinical diagnostics market, with truly unique and innovative services with high positive impact for patient care. In combination with ViraCor and Diatherix for infectious diseases, Boston Heart for cardiovascular, and EGL for genetic diseases, NTD's expertise in prenatal screening reinforces the Group's position in advanced diagnostic testing to better serve the global healthcare community".
For more information about Eurofins, please visit www.eurofins.com or contact:
Eurofins Scientific Group
Phone: +32 2 766 1620
Notes for the editor:
Eurofins - a global leader in bio-analysis
Eurofins Scientific believes it is the world leader in food, environment and pharmaceutical products testing, as well as one of the global market leaders in agroscience, genomics, discovery pharmacology and central laboratory services. In addition, Eurofins is one of the key emerging players in specialty clinical diagnostic testing in Europe and the USA.
With over 23,000 staff in more than 225 laboratories across 39 countries, Eurofins offers a portfolio of over 130,000 validated analytical methods for evaluating the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group provides its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.
As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the expanding demands of regulatory authorities and healthcare practitioners around the world.
The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA,
Bloomberg ERF FP).
This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific’ management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantee can be made as to their validity.